Inhibrx Biosciences Reported $36.7 Million Q2 Loss on Aug. 13

Inhibrx Biosciences reported a $36.7 million net loss for the second quarter of 2026 on Aug. 13, its latest disclosed quarterly results, with two clinical programs in ongoing trials.

Revenue was $0 for the quarter, compared with $1.3 million a year earlier. The company recorded a loss of $2.34 per share, both basic and diluted.

Inhibrx described itself as a clinical-stage biopharmaceutical company with two programs in ongoing clinical trials.